Zobrazeno 1 - 10
of 115
pro vyhledávání: '"M Hojnik"'
Autor:
Hendrik Schulze-Koops, Josef S Smolen, Jordi Gratacós, Roberto Caporali, Lingnan Li, Sreekumar G. Pillai, Peter Nash, Masato Okada, Philip J. Mease, Christophe Sapin, Hasan Tahir, Inmaculada de la Torre, M. Hojnik, Philippe Goupille, Soyi Liu Leage
Publikováno v:
Annals of the Rheumatic Diseases
ObjectivesSPIRIT head-to-head (H2H) is a 52-week (Wk) trial comparing ixekizumab (IXE) with adalimumab (ADA) for simultaneous American College of Rheumatology (ACR)50 and Psoriasis Area and Severity Index (PASI)100 responses in 566 patients (distribu
Autor:
Xiaoqi Li, Robert Landewé, C. Lukas, Hilde Carlier, Proton Rahman, Soyi Liu-Leage, Lianne S. Gensler, M. Hojnik, Denis Poddubnyy, David J. Adams, F. Van den Bosch
Publikováno v:
Revue du Rhumatisme. 88:A108-A109
Autor:
W. P. Maksymowych, X. Baraliakos, R. G. Lambert, R. B. M. Landewé, D. Sandoval, H. Carlier, J. Lisse, X. LI, M. Hojnik, M. Østergaard
Publikováno v:
Annals of the Rheumatic Diseases. 81:399.1-399
BackgroundIxekizumab (IXE) has demonstrated clinical efficacy in patients with active non-radiographic axial spondyloarthritis (nr-axSpA) together with significant repair of structural lesions in the sacroiliac joint (SIJ) on MRI. There is, however,
Autor:
Ivo Valter, Arthur Kavanaugh, Vinod Chandran, M. Hojnik, Philip J. Mease, Gaia Gallo, Sreekumar G. Pillai, Lisa Kerr, Hasan Tahir, L. Zhang, David H. Adams, Laura C. Coates
Publikováno v:
Rheumatology. 59
Background This study evaluated efficacy and safety of continuing vs. withdrawing ixekizumab (IXE), an IL-17A antagonist, in psoriatic arthritis (PsA) patients who achieved sustained minimal disease activity (MDA) on IXE and re-treating with IXE if r
Autor:
F. Ganz, Ediz Dalkilic, S.A.L. Lima, R. Horváth, Wolf-Henning Boehncke, M. Okada, Ennio Lubrano, M. Hojnik
Publikováno v:
Journal of the European Academy of Dermatology and Venereology, Vol. 34, No 9 (2020) pp. 2035-2043
Background Psoriatic arthritis (PsA) is a chronic and debilitating disease that can be managed by different clinical specialists. Objectives The objective of theLOOPstudy was to evaluate the impact of clinical specialty setting on the time to diagnos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::defd6b59ba77264778880491aacfba81
http://hdl.handle.net/11452/30591
http://hdl.handle.net/11452/30591
Autor:
Jan Brzezicki, Ramon Toro-Torres, Juan Cruz Rizo Rodriguez, Eric C. Mueller, Atul Deodhar, Anna Dudek, Gunther Neeck, Roger J. Diegel, Maria Greenwald, Lianne S. Gensler, Hitoshi Goto, Judith Carrio, Seung Jae Hong, Cassandra M. Skinner, Yoshinori Taniguchi, Tatsuya Atsumi, Mikkel Østergaard, Shigeru Honjo, Clemens Scheinecker, Heinrich Resch, Rafal Plebanski, Yoshifuji Matsumoto, David H. Adams, Min Chan Park, Richard Roseff, David H. Goddard, Hiroaki Dobashi, Steven C. Kimmel, Johannes Grisar, Christine Thai, Sergio Duran Barragan, Chang Keun Lee, Tetsuya Tomita, Frederic Morin, Roel Querubin, Jose Maldonado Cocco, Craig D. Scoville, Philip J. Mease, Luminita Tronaru, Kurisu Tada, Denis Poddubnyy, Mohamed B. Sebai, Federico Ariel, Eleonora Lucero, Mark D. Harris, Kari K. Eklund, Melvin Churchill, Jeffrey L. Kaine, Cesar Ricardo Ramos Remus, Francisco Fidencio Cons Molina, Kazuhiro Hatta, Eun Bong Lee, Joachim Sieper, Alan Kivitz, Yukitaka Ueki, Jorge Velasco, Seong Wook Kang, Jürgen Braun, Sang-Heon Lee, Xiaoqi Li, Kentaro Inui, Leena Paimela, Michael E. Sayers, Arthur R. Mabaquiao, Antonio Scafuto Scotton, Sylke Wagner, Carlos Pantojas, Janina Drabiszcak-Piatkowska, Ana Maria Ramazan, Steven J. Klein, Proton Rahman, M. Hojnik, Marleen G H van de Sande, Tania L. Rivera, Amarilis Perez-De Jesus, Kathleen P. Flint, Jyothi R. Mallepalli, John E. Hull, Karel Pvelka, Evgeniya Schmidt, Mary P. Howell, Yuya Takakubo, Gaia Gallo, Walter P. Maksymowych, Joseph C. Shanahan, Marek Krogulec, Aaron Alejandro Barrera Rodriguez, Cesar Francisco Pacheco Tena, Anna Karjalainen, Pentti Jarvinen, Oscar Soto-Raices, Zdenek Dvorak, Désirée van der Heijde, Tokutaro Tsuda, Galina Matsievskaya, Sergey Yakushin, Eva Dokoupilova, Ann Leung, Luis Roimicher, Daniela Opris-Belinski, Pawel Hrycai, Tomasz Blicharshi, Kiyoshi Matsui, Hilde Carlier, Olga Ershova, Alberto Berman, Tae-Hwan Kim, Eric A. Peters, Marina Stanislav, Ana Claudia Melazzi, Martina Malcova, Louis Bessette, Sang-Hoon Lee, Helena Marzo-Ortega, Andrey Rebroy, Diego O. Viola, Rodolfo A Pardo Hidalgo
Publikováno v:
Lancet, 395(10217), 53-64
Lancet, 395(10217), 53-64. Elsevier Limited
Lancet, 395(10217), 53-64. Elsevier Limited
Summary Background Ixekizumab, a high-affinity interleukin-17A (IL-17A) monoclonal antibody, has previously shown efficacy in radiographic axial spondyloarthritis (also known as ankylosing spondylitis). We aimed to evaluate the efficacy and safety of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de58e8a78134c8e494ab8c28ac8b159f
https://hdl.handle.net/1887/3181441
https://hdl.handle.net/1887/3181441
Autor:
Mikkel Østergaard, Fangyi Zhao, M. Hojnik, Louis Bessette, Tetsuya Tomita, David H. Adams, Gaia Gallo, A. Deodhar, Helena Marzo-Ortega, Denis Poddubnyy, J. Sieper, Lianne S. Gensler, Hilde Carlier, Walter P. Maksymowych, Tae-Hwan Kim, Maxime Dougados, A. Leung, D. van der Heijde
Publikováno v:
Revue du Rhumatisme. 87:A165-A166
Introduction Ixekizumab, un anticorps monoclonal ayant une forte affinite pour l’IL-17A, a deja demontre son efficacite dans la spondyloarthrite axiale radiographique [1] , [2] . COAST-X (NCT02757352) est une etude de phase 3 qui a permis d’evalu
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
P. J. Mease, Josef S. Smolen, Philippe Goupille, H. Schultze-Koops, Lingnan Li, M. Hojnik, Soyi Liu-Leage, Peter Nash, Sreekumar G. Pillai, G. Amanda, H. Tahir
Publikováno v:
Revue du Rhumatisme. 87:A166
Introduction De nombreux DMARD biologiques (bDMARD) sont disponibles dans le traitement du rhumatisme psoriasique (RPso), mais il existe peu d’etudes de comparaison directe de leur efficacite et tolerance. En outre, l’efficacite des bDMARD avec o
Autor:
Jianhua Xu, F. Zhang, Chunde Bao, Lindi Jiang, L. Bi, Yongfei Fang, M. Hojnik, Denis Poddubnyy, L. Wu, Xiao Zhang, Feng Huang, D. He
Publikováno v:
Spondyloarthritis – clinical aspects (other than treatment).
Background National observational studies, mostly from Europe, have reported some differences between radiographic axial spondyloarthritis (axSpA) and non-radiographic axSpA (nr-axSpA). Objectives To compare demographic and clinical characteristics o